Home   |   Pipeline   |

Strategy 1.
It is applied to remove unwanted HPs, which induce tissue degeneration or suppress tissue regeneration. Neutralizing antibodies against the HPs will be used to sequester extracellular HPs in degenerating tissues. This strategy includes Anti-PROX1 antibody-mediated regeneration therapy for retinal degenerative diseases.

Strategy 2.
It is applied to supply exogenous HPs, which are necessary for the maintenance and regeneration of tissues. Recombinant HPs will be introduced to the disease tissues, which degenerate due to a deficiency of the HPs. Neuroprotective OTX2 and axon growth stimulating VAX1 proteins are belong to this class.